Oral BMS-354825 rescues Gleevec-resistant CML

被引：0
|
作者：
不详
机构：
来源：
CANCER BIOLOGY & THERAPY | 2004年 / 3卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：700 / 700
页数：1
相关论文
共 50 条
  • [21] Action of dasatinib (BMS-354825), a novel, oral, multi-targeted kinase inhibitor, on human prostate cancer cells.
    Nam, S
    Kim, D
    Cheng, JQ
    Zhang, SM
    Lee, JH
    Buettner, R
    Mirosevich, J
    Lee, F
    Jove, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9028S - 9028S
  • [22] Mechanism of drug resistance to dasatinib (BMS-354825) and imatinib in chronic myelogenous leukemia cells.
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Broxmeyer, Hal E.
    Ohyashiki, Kazuma
    BLOOD, 2006, 108 (11) : 404A - 404A
  • [23] The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor.
    Tokarski, JS
    Newitt, J
    Lee, FY
    Lornbardo, L
    Borzilleri, R
    Kish, K
    Xie, DL
    Zhang, Y
    Cheng, JD
    Kiefer, SE
    Chang, CYJ
    Klei, HE
    BLOOD, 2004, 104 (11) : 160A - 160A
  • [24] Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients: Impact and fate of imatinib-resistant clones in dasatinib-treated patients.
    Branford, S
    Hughes, T
    Nicoll, J
    Paquette, R
    Bleickardt, E
    Sawyers, C
    Shah, N
    BLOOD, 2005, 106 (11) : 132A - 132A
  • [25] Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
    Luo, Feng R.
    Yang, Zheng
    Camuso, Amy
    Smykla, Richard
    McGlinchey, Kelly
    Fager, Krista
    Flefleh, Christine
    Castaneda, Stephen
    Inigo, Ivan
    Kan, David
    Wen, Mei-Li
    Kramer, Robert
    Blackwood-Chirchir, Anne
    Lee, Francis Y.
    CLINICAL CANCER RESEARCH, 2006, 12 (23) : 7180 - 7186
  • [26] Mass balance, pharmacokinetics and metabolism of [14C] BMS-354825 in healthy male subjects
    Wu, C. -Y.
    Callegari, F.
    McCann, B.
    Sanil, A.
    Reitberg, D. P.
    Hawthorne, D.
    Christopher, L.
    Cui, D.
    Griffin, T.
    EJC SUPPLEMENTS, 2006, 4 (12): : 50 - 50
  • [27] Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
    Alex Y Chang
    Miao Wang
    BMC Cancer, 13
  • [28] Dasatinib (BMS-354825) has increased activity against Bcr-Abl compared to imatinib in primary CML cells in vitro, but does not eradicate quiescent CML stem cells.
    Copland, M
    Hamilton, A
    Baird, JW
    Barow, M
    Allan, EK
    Elrick, LJ
    Holyoake, TL
    BLOOD, 2005, 106 (11) : 205A - 205A
  • [29] Identification of pharmacogenomic markers for predicting sensitivity to BMS-354825, a SRC/ABL kinase inhibitor.
    Clark, E
    Reeves, KA
    Han, X
    Shaw, PM
    Fairchild, C
    Wu, Q
    Platero, S
    Wong, TW
    Lee, F
    Huang, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 194S - 194S
  • [30] BMS-354825:一种新的酪氨酸激酶抑制剂
    傅明伟
    王建祥
    国际输血及血液学杂志, 2005, (06) : 532 - 535
12345